Clinical significance of Fas, VEGF, and EGFR expression in advanced gastric carcinoma.

Authors

null

Sheng Ye

Department of Oncology, First Affiliated Hospital

Sheng Ye , Jian Rong , Xiaohong Fu , Tongyu Lin

Organizations

Department of Oncology, First Affiliated Hospital , Department of Anesthesiology, First Affiliated Hos, The Twelfth Hospital of Guangzhou City, Department of Medical Oncology, Sun Yat-sen Univer

Research Funding

No funding sources reported

Background: Researches had proved that apoptotic signal proteins Fas-mediated cellular apoptosis influenced development of gastric carcinoma and affected survival of gastric carcinoma patients. Epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF) over expression had been associated with poor survival in several cancers including gastric carcinoma. Methods: Immunohisto-chemistry was performed to detect Fas, EGFR and VEGF protein expression in 60 newly diagnosed patients with gastric carcinoma in the First Affiliated Hospital of Sun Yat-sen University from November 1999 to June 2005. Clinical Data of these patients were reviewed. Time to progression (TTP) and overall survival (OS) were compared by log-rank test according to the expression status of Fas, EGFR and VEGF. Results: There were 40 males and 20 females, all patients were stage IV. All patients were treated with infused fluorouracil plus leucovorin and oxaliplatin or paclitaxel. The positive rate of Fas, EGFR and VEGF in gastric carcinoma was 73.3%, 35% and 40% respectively. TTP for patients with Fas positive was significantly superior to patients with Fas-negative (p<0.05). EGFR and VEGF were not correlated with TTP (p>0.05). Fas, EGFR and VEGF were not associated with overall survival(p>0.05). Conclusions: Fas, EGFR and VEGF are often expressed in gastric carcinoma. Fas expression is correlated with longer TTP. EGFR and VEGF expression were not associated with TTP. Fas, EGFR and VEGF were not a prognostic factor for OS.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2013 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session A: Cancers of the Esophagus and Stomach

Track

Cancers of the Esophagus and Stomach

Sub Track

Translational Research

Citation

J Clin Oncol 31, 2013 (suppl 4; abstr58)

DOI

10.1200/jco.2013.31.4_suppl.58

Abstract #

58

Poster Bd #

B2

Abstract Disclosures

Similar Abstracts